Session 6: Insights from Health Care Systems on Bispecifics: Patient Treatment, Monitoring and Transition of Care : Episode 11
Future Perspectives on the Role of Bispecifics in MM
Doctors discuss the potential of bispecific therapies being used in earlier lines of treatment for multiple myeloma, and the need for understanding and reducing toxicities as much as possible.
EP: 1.Overview of Treatment Options for the Management of Relapsed/Refractory Multiple Myeloma (R/R MM)
EP: 2.Data Updates on BCMA-Targeting Bispecific Antibodies in R/R MM Treatment
EP: 3.MonumenTAL-1: Evaluating the Anti- GPRC5D-Targetings Bispecific in R/R MM
EP: 4.FCRH5-Targeting and Other Emerging Bispecifics in R/R MM
EP: 5.Incorporating Teclistamab in R/R MM: Insights from Clinical Practices Across the US
EP: 6.Step-up Dosing and Monitoring in Patients with MM on Bispecifics: Health System Perspectives
EP: 7.Best Practices for Transition of Care in Patients with MM on Teclistamab
EP: 8.Managing Infections and Other Toxicities Associated with Bispecifics in MM
EP: 9.Sequencing BCMA-Targeting Bispecifics in R/R MM Treatment
EP: 10.Choosing Between BCMA and Non-BCMA Bispecifics in Multiple Myeloma Treatment
Now Viewing
EP: 11.Future Perspectives on the Role of Bispecifics in MM
EP: 12.Key Takeaways from Health Care Systems on the Role of Bispecifics in MM
EP: 13.Teclistamab Reviewed as Potential Treatment Option in Relapsed/Refractory Multiple Myeloma
EP: 14.Treatment Recommendations for Relapsed Multiple Myeloma
Recent Videos
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.")
Related Content
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025Podcast
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
